Literature DB >> 7333348

Simultaneous tubular excretion and reabsorption of pindolol in man.

L Balant, K Muir, P Dayer, A Gorgia, J L Eberlin, J Estreicher, J Fabre.   

Abstract

The plasma concentrations of pindolol have been examined following the administration of single doses of 15 mg tablets to eight healthy male subjects. The apparent half-life of elimination in plasma (t1/2 = 4.05 h) and in urine (t1/2 = 3.21 h) was calculated using conventional pharmacokinetic methods. The renal clearance was estimated by plotting urinary excretion rates versus plasma concentrations; for all subjects these plots were curved. In addition to these graphical estimations, the plasma concentrations of pindolol and the urinary excretion data for each volunteer were simultaneously fitted using a one or two-compartment open body model; a computer program using non-linear regression algorithms was used. This procedure did not give an adequate fit to the data. Another type of data analysis, using a population - based model, permitted us to show that the renal elimination of pindolol in man comprises of two separate processes - tubular secretion and reabsorption, which was partially saturable under the experimental conditions. The theoretical relevance and clinical significance of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333348     DOI: 10.1007/bf00609590

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Pharmacokinetics and clearances related to renal processes.

Authors:  E R Garrett
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-04

2.  Single and multiple dose pharmacokinetics of pindolol.

Authors:  R Gugler; G Bodem
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

3.  Compartmental analysis--I: LINDE, a program using an analytical method of integration with constituent matrices.

Authors:  J Estreicher; C Revillard; J R Scherrer
Journal:  Comput Biol Med       Date:  1979       Impact factor: 4.589

4.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15
  4 in total
  8 in total

1.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

Authors:  L Borgström; L Nyberg; S Jönsson; C Lindberg; J Paulson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

2.  Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

3.  Pharmacokinetics of nadolol in healthy subjects.

Authors:  M Schäfer-Korting; N Bach; H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Estimation of the absolute oral bioavailability of pindolol by two analytical methods.

Authors:  M Guerret; G Cheymol; J P Aubry; A Cheymol; D Lavene; J R Kiechel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.

Authors:  A S Gross; A J McLachlan; I Minns; J B Beal; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

6.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

7.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Authors:  P H Hinderling; O Schmidlin; J K Seydel
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

Review 8.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.